School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Apitope International NV, Diepenbeek, Belgium.
Front Immunol. 2021 Apr 14;12:654201. doi: 10.3389/fimmu.2021.654201. eCollection 2021.
Immunotherapy with antigen-processing independent T cell epitopes (apitopes) targeting autoreactive CD4 T cells has translated to the clinic and been shown to modulate progression of both Graves' disease and multiple sclerosis. The model apitope (Ac1-9[4Y]) renders antigen-specific T cells anergic while repeated administration induces both Tr1 and Foxp3 regulatory cells. Here we address why CD4 T cell epitopes should be designed as apitopes to induce tolerance and define the antigen presenting cells that they target . Furthermore, we reveal the impact of treatment with apitopes on CD4 T cell signaling, the generation of IL-10-secreting regulatory cells and the systemic migration of these cells. Taken together these findings reveal how apitopes induce tolerance and thereby mediate antigen-specific immunotherapy of autoimmune diseases.
免疫疗法用抗原处理独立的 T 细胞表位(apitopes)针对自身反应性 CD4 T 细胞已转化为临床,并已显示调节 Graves 病和多发性硬化症的进展。模型表位(Ac1-9[4Y])使抗原特异性 T 细胞无反应,而重复给药诱导 Tr1 和 Foxp3 调节细胞。在这里,我们探讨为什么 CD4 T 细胞表位应该被设计为诱导耐受的表位,并确定它们针对的抗原呈递细胞。此外,我们揭示了用表位治疗对 CD4 T 细胞信号转导、IL-10 分泌调节细胞的产生以及这些细胞的全身迁移的影响。总之,这些发现揭示了表位如何诱导耐受,从而介导自身免疫性疾病的抗原特异性免疫治疗。